Avidity Partners Management as of Sept. 30, 2025
Portfolio Holdings for Avidity Partners Management
Avidity Partners Management holds 43 positions in its portfolio as reported in the September 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Dianthus Therapeutics (DNTH) | 28.7 | $126M | 3.2M | 39.35 | |
| Cg Oncology (CGON) | 14.7 | $65M | 1.6M | 40.28 | |
| Medtronic SHS (MDT) | 4.1 | $18M | 191k | 95.24 | |
| Boston Scientific Corporation (BSX) | 3.7 | $16M | 164k | 97.63 | |
| Oruka Therapeutics (ORKA) | 2.9 | $13M | 660k | 19.23 | |
| Bristol Myers Squibb (BMY) | 2.6 | $12M | 258k | 45.10 | |
| Natera (NTRA) | 2.6 | $11M | 70k | 160.97 | |
| Danaher Corporation (DHR) | 2.5 | $11M | 55k | 198.26 | |
| Teva Pharmaceutical Inds Sponsored Ads (TEVA) | 2.3 | $10M | 510k | 20.20 | |
| Perspective Therapeutics Com New (CATX) | 2.3 | $10M | 3.0M | 3.43 | |
| Jade Biosciences Com New (JBIO) | 2.2 | $9.7M | 1.1M | 8.63 | |
| Pfizer (PFE) | 2.1 | $9.3M | 366k | 25.48 | |
| Thermo Fisher Scientific (TMO) | 2.1 | $9.2M | 19k | 485.02 | |
| Context Therapeutics (CNTX) | 2.0 | $8.7M | 9.0M | 0.97 | |
| Genmab A/s Sponsored Ads (GMAB) | 1.7 | $7.6M | 248k | 30.67 | |
| Mestera (MTSR) | 1.7 | $7.4M | 141k | 52.33 | |
| UnitedHealth (UNH) | 1.4 | $6.1M | 18k | 345.30 | |
| Arvinas Ord (ARVN) | 1.4 | $6.0M | 698k | 8.52 | |
| AmerisourceBergen (COR) | 1.4 | $5.9M | 19k | 312.53 | |
| Encompass Health Corp (EHC) | 1.2 | $5.3M | 42k | 127.02 | |
| Johnson & Johnson (JNJ) | 1.1 | $5.0M | 27k | 185.42 | |
| Cigna Corp (CI) | 1.1 | $4.8M | 17k | 288.25 | |
| Abbvie (ABBV) | 1.0 | $4.6M | 20k | 231.54 | |
| McKesson Corporation (MCK) | 1.0 | $4.5M | 5.8k | 772.54 | |
| Carlsmed | 1.0 | $4.3M | 322k | 13.39 | |
| Kenvue (KVUE) | 1.0 | $4.3M | 265k | 16.23 | |
| Immunic (IMUX) | 0.9 | $4.1M | 4.7M | 0.88 | |
| Arcutis Biotherapeutics (ARQT) | 0.9 | $4.0M | 214k | 18.85 | |
| EXACT Sciences Corporation (EXAS) | 0.9 | $4.0M | 74k | 54.71 | |
| Phathom Pharmaceuticals (PHAT) | 0.8 | $3.6M | 306k | 11.77 | |
| Repligen Corporation (RGEN) | 0.7 | $3.1M | 23k | 133.67 | |
| ACADIA Pharmaceuticals (ACAD) | 0.7 | $3.1M | 144k | 21.34 | |
| Ascendis Pharma A/s Sponsored Adr (ASND) | 0.7 | $2.9M | 15k | 198.81 | |
| Enliven Therapeutics (ELVN) | 0.7 | $2.9M | 140k | 20.47 | |
| Beam Therapeutics (BEAM) | 0.6 | $2.7M | 112k | 24.27 | |
| Scynexis Com New (SCYX) | 0.6 | $2.6M | 3.4M | 0.77 | |
| Healthequity (HQY) | 0.5 | $2.4M | 25k | 94.77 | |
| Wave Life Sciences SHS (WVE) | 0.5 | $2.2M | 298k | 7.32 | |
| Xenon Pharmaceuticals (XENE) | 0.5 | $2.1M | 53k | 40.15 | |
| Akero Therapeutics (AKRO) | 0.4 | $1.9M | 41k | 47.48 | |
| Insmed Com Par $.01 (INSM) | 0.4 | $1.7M | 12k | 144.01 | |
| Karyopharm Therapeutics Com New (KPTI) | 0.2 | $880k | 135k | 6.54 | |
| Immuneering Corp Class A Com (IMRX) | 0.1 | $636k | 91k | 7.00 |
